Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $36,300.00 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $25.00, for a total transaction of $36,300.00. Following the completion of the transaction, the insider directly owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This trade represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.

Nurix Therapeutics Price Performance

NRIX opened at $24.42 on Friday. The stock has a market cap of $2.67 billion, a P/E ratio of 10.57 and a beta of 1.82. The stock’s 50 day simple moving average is $25.11 and its 200 day simple moving average is $21.16. Nurix Therapeutics, Inc. has a 1-year low of $9.71 and a 1-year high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. Research analysts expect that Nurix Therapeutics, Inc. will post 1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Nurix Therapeutics by 95.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after buying an additional 620 shares in the last quarter. Nykredit A S purchased a new position in Nurix Therapeutics during the second quarter worth $32,000. Integrated Wealth Concepts LLC purchased a new position in Nurix Therapeutics during the second quarter worth $33,000. KBC Group NV purchased a new position in Nurix Therapeutics during the first quarter worth $34,000. Finally, Avalon Trust Co purchased a new position in Nurix Therapeutics during the second quarter worth $64,000.

Analyst Ratings Changes

Several analysts have weighed in on the company. Oppenheimer upped their target price on Nurix Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday. UBS Group lifted their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $34.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, October 13th. Mizuho boosted their price objective on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Stifel Nicolaus set a $41.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.79.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.